Abstract:Our aim was to construct the eukaryotic expressional system of single-chain antibody (ScFv(2F9)) derived from a new clone of monoclonal antibody named ZCH-7-2F9 against human CD14 antigen, and to obtain the ScFv(2F9) protein with a high biological activity for further studies on ScFv(2F9) immunotoxin and other kinds of genetically engineered antibodies. Primers were synthesized according to the gene sequence of ScFv(2F9), 4 tandem glysines and 1 serine (Gly4Ser)3 linker and multiple cloning site(MCS) of pSectag2A vector, which included SfiI and EcoRI enzyme cleaving site, 6 x His and stop code TGA sequences. ScFv(2F9) gene was amplified through splicing by overlap extension (SOE) using the high fidelity Taq polymerase. Then the gene was cloned to pGEM-T easy and pSectag2A vectors. Positive recombinants (pSectag2A/ScFv(2F9)) were identified through enzyme cleaving and sequenced before expression. The recombinant plasmids were transfected into Chinese hamster ovary (CHO) cells for expression. The relative molecular weight (MW) and the binding activity of the interesting protein were determined by SDS-PAGE, Western-blot and flow cytometry (FCM), respectively. The scFv(2F9) V-H is a member of the IgH gene family V, subgroup and the scFv(2F9) V-L gene belongs to the Ig(k) gene family V-10 subgroup. The recombined ScFv(2F9) gene was identified to be functional by sequencing and expressing. The interesting protein could be detected in the culture supernatant of transformed CHO cells with a MW of 31 kDa. The blocking test showed that the positive cell percentages, the mean fluorescence intensity (MFI) and the peak of channel (peak Ch) were reduced by 90.02%, 63.3% and 63.38%, respectively after blockage of ScFv(2F9). The ScFv(2F9) gene was cloned and the interest protein against human CD14 antigen has been successfully expressed in eukaryotic cells with a high biological activity, which lays the foundation for further studies on its immunotoxin and other kinds of engineered antibodies.

Binding Activity Difference of Anti-Cd20 Scfv-Fc Fusion Protein Derived from Variable Domain Exchange.

Molecular Insights into the Binding Selectivity of a Synthetic Ligand DAAG to Fc Fragment of IgG

Human IgG1 Cgamma1 Domain is Crucial for the Bioactivity of the Engineered Anti-Cd20 Antibodies.

Human IgG 1 C γ 1 Domain Is Crucial for the Bioactivity of the Engineered Anti-CD 20 Antibodies

Molecular Modeling and Affinity Determination of Scfv Antibody: Proper Linker Peptide Enhances Its Activity

Effects of Anchor Structure and Glycosylation of Fcγ Receptor III on Ligand Binding Affinity.

High Antitumor Activity of Sortase A-generated Anti-Cd20 Antibody Fragment Drug Conjugates

The design, construction and function of a new chimeric anti-CD20 antibody.

Design and assembly of anti-CD16 ScFv antibody with two different linker peptides.

Construction and Expression of Single-Chain Antibody Derived from a New Clone of Monoclonal Antibody Against Human CD14 in CHO Cells

Functional Expression of Chimeric Fab of an Anti-Cd40l Mab: Vector Design and Culture Condition Optimization.

[Construction and Expression of Prokaryotic Vector of Single Chain Antibody Derived from a New Clone of Anti-Cd14 Antibody ZCH-7-2F9].

Optimization and Modification of Anti-Rhtnf-α Single Chain Variable Fragment Antibody: Effective in Vitro Affinity Maturation and Functional Expression of Chimeric Fab.

The difference of binding epitopes on human CD16 (FcγRIII) interacted with hIgG1 and monoclonal antibody B88-9

Systematic analysis of Fc mutations designed to enhance binding to Fc-gamma receptors

Design of a Novel Fab-Like Antibody Fragment with Enhanced Stability and Affinity for Clinical use

Anti-Cd20 Antibody with Multimerized Fc Domains: A Novel Strategy to Deplete B Cells and Augment Treatment of Autoimmune Disease

Rigid crosslinking of the CD3 complex leads to superior T cell stimulation

Functional Antibody CDR3 Fusion Proteins with Enhanced Pharmacological Properties

Binding Domain on Cd22 Molecules Contributing to the Biological Activity of T Cell-Engaging Bispecific Antibodies

Engineered Soluble Monomeric IgG1 Fc with Significantly Decreased Non-Specific Binding